U043 Management and Special Considerations in Unique Hidradenitis Suppurativa Populations: A Focus on Down Syndrome, Exogenous Hormone Use, and the Elderly
DESCRIPTION
This focus session will explore the complexities of hidradenitis suppurativa management in three unique patient populations: individuals with Down syndrome, patients receiving exogenous hormone therapy (including gender affirming care, contraception, fertility, or hypogonadism), and the elderly. Through case-based discussions, attendees will gain insight into the nuanced presentations, risk factors, and therapeutic challenges specific to these groups. The session will cover strategies for adapting standard HS treatment in these special populations. It will emphasize the need for multidisciplinary care, highlight relevant clinical data, and encourage consideration of ethical, psychosocial, and quality-of-life factors in management decisions.
LEARNING OBJECTIVES
Recognize the unique clinical features and therapeutic challenges of HS in patients with Down syndrome, those undergoing exogenous hormone therapy, and elderly individuals.
Apply evidence-based management approaches in these special populations with HS.
Highlight current gaps in the literature and opportunities for research in managing HS among these populations.
DIRECTOR
Sherry Yang, MD, FAAD
CO-DIRECTOR
Venessa Pena-Robichaux, MD, FAAD
SPEAKERS
Katrina Lee, MD, FAAD
Jillian Rork, MD, FAAD
Katherine Sherif
DISCLOSURES
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Venessa Pena-Robichaux, MD, FAAD
Osquo – Other(Stock);
Jillian Rork, MD, FAAD
No financial relationships exist with ineligible companies.
Katherine Sherif
No financial relationships exist with ineligible companies.
Sherry Yang, MD, FAAD
American College of Physicians – Other(Honoraria); Incyte – Investigator(Grants/Research Funding);